Talis Biomedical Corporation (TLIS) - Dhuwit awis saben saham

Lambang korporat lan logo Talis Biomedical Corp. (TLIS)

Talis Biomedical (TLIS) maintains stability through unique patents for rapid tests, as evidenced by the cash per share value, which remains at 1.89. However, disrupted Asian supply chains and sanctions are eroding revenue. The current phase is characterized by stagnation and preparations for asset liquidation, a trend clearly reflected in the liquidity price action on this chart.

TLIS - Dhuwit awis saben siji saham talis.bio ing rentang 04.07.2022 - 07.09.2024

Rincian analitis perusahaan Talis Biomedical

- nilai saham lan prakiraan konsensus rega:
- rincian posisi dhuwit lan arus kas:
Analisis umum perusahaan:TLIS, Talis Biomedical Corporation
Produk asli Talis Biomedical Corp

Financial stability is a critical survival factor for Talis Biomedical (TLIS) amid fierce competition in the rapid testing sector. This cash per share metric is calculated as the ratio of liquid reserves to the number of issued securities. The metric determines the intrinsic value of an investor's stake backed by real capital. In the context of high operating expenses for the IT platform, this chart demonstrates the company's ability to withstand market shocks. Excess cash protects the business but may signal a slowdown in expansion rates.